公司资料
Xeris Pharmaceuticals 股价、新闻与催化剂
- 股票代码:
- XERS
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
8.52 USD (-0.93%)
收盘价
最后更新: 2026年8月17日
1.04B USD
市值
股价为何变动
As of Aug 17, 2026, XERS closed down 0.93% at $8.52. No new same-company headline was identified in the current news window.
公司概览
Specialty Biopharmaceutical Portfolio
Xeris Biopharma develops and commercializes products across endocrinology and neurology, using formulation technologies to improve administration and treatment reliability.
Endocrine Products
Recorlev is an oral cortisol-synthesis inhibitor for endogenous hypercortisolemia in Cushing's syndrome. Gvoke is a ready-to-use liquid glucagon for severe hypoglycemia. Keveyis is an oral therapy for primary periodic paralysis. Together, the portfolio gives Xeris a multi-product commercial platform serving specialist prescribers and patients with chronic or episodic endocrine disorders.
未来催化剂
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。